

Letter to the editors

Dears Sirs,

I have read in your journal (vol. 18, No 3) a long general review on the past, present and future of anthracyclins, and found that it dealt mostly with Farmitalia products, and hardly with THP adriamycin and aclacinomycin.

Now, in my sense, the latter represent the only two consistent projects in the field.

I am sorry to suspect that "Cancer, Chemotherapy and Pharmacology" should be supported by subterranean sponsors.

I would appreciate your publishing this letter in "Cancer, Chemotherapy and Pharmacology".

Georges Mathé
Institut de Cancérologie et d'Immunogénétique
Groupe Hospitalier Paul-Brousse
F-94800 Villejuif, France

Reference

Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B (1986) Anthracycline analogs: The past, present, and future (A Review). *Cancer Chemother Pharmacol* 18: 185

Received March 5, 1987

Editorial note

We accept the fact that Professor Mathé has a right to his opinions however offensive they may be. However, we wish to point out very firmly that there is no "subterranean", or for that matter overt sponsorship of *Cancer Chemotherapy and Pharmacology* by any drug company.

S. K. Carter and T. J. McElwain

Authors' note

Dr. Mathé's letter is inappropriate and an affront both to the authors of the article and the editors of *Cancer Chemotherapy and Pharmacology*. Our reason for preparing this article was that the four agents reviewed are in active clinical trial in the U.S. and elsewhere. Other anthracyclines have been, or are presently, under study in many other countries, and we provided this information in a table. The article could not be encyclopedic for all agents in this class. No drug company (including Farmitalia) influenced this review in any way. We are scientists and clinicians and do not write articles to promote drugs for commercial purposes.

Raymond B. Weiss,
Walter Reed Army Medical Center,
Washington, DC, USA

Brian Leyland-Jones,
National Cancer Institute,
Bethesda, MD, USA